FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1040989942> ?p ?o ?g. }

• W1040989942 endingPage "621" @default.
• W1040989942 startingPage "621" @default.
• W1040989942 abstract "Abstract Background: Overall survival (OS) in older patients (pts) with AML and poor-risk cytogenetics is only ~2-3 months (mos) (Burnett, Cancer, 2007). Often these pts receive only palliative treatment (Tx) with best supportive care (BSC). Low-dose Ara-C (LDAC) provides no OS benefit in pts with poor cytogenetics (Döhner, Blood, 2010). Typically, intensive chemotherapy (IC) is either not suitable for older AML pts with poor cytogenetics or, when it is used, provides no OS benefit (Kantarjian, Blood, 2010). The phase 3, multicenter, randomized, open-label AZA-AML-001 trial showed azacitidine (AZA) Tx in older pts with newly diagnosed AML (>30% bone marrow [BM] blasts) prolonged median OS by ~4 mos vs conventional care regimens (CCR) (10.4 vs 6.5 mos; p=0.1009) and improved 1-year survival (46.5% vs 34.2%) (Dombret, EHA, 2014). Cytogenetic risk is a prognostic indicator in elderly AML and a frequent determinant of Tx approach and outcomes. Objective: To determine the effect of Tx with AZA vs CCR on OS and 1-year survival in AZA-AML-001 pt subgroups based on cytogenetic risk classification. Methods: Pts aged ≥65 years with newly diagnosed de novo or secondary AML who were ineligible for transplant, with intermediate- or poor-risk cytogenetics (pts with favorable cytogenetics were excluded from study), ECOG performance status 0-2, and WBC count ≤15x109/L, were eligible. Before randomization, each pt was preselected to receive 1 of 3 commonly used CCR for older pts with AML, per investigator choice: IC (standard 7+3 regimen), LDAC (20 mg SC BID x 10 days/28-day cycle), or BSC only. Pts were then randomized to AZA (75 mg/m2/day SC x 7 days/28-day cycle) or to CCR, in which case they received their preselected Tx. The primary endpoint was OS. Cytogenetic risk groups were assessed per NCCN criteria by central review: intermediate (INT; all cases), intermediate with normal karyotype (cytogenetic normal [CN]), and poor. Survival at 1 year was compared between Tx. Median OS for AZA vs CCR was calculated using Kaplan-Meier methods, hazard ratios (HR) and 95% confidence intervals (CI) were determined by unstratified Cox proportional hazards model, and p values by log-rank test. Results: In all, 488 pts were randomized, 241 to AZA and 247 to CCR. Cytogenetic risk was balanced between Tx groups: 315 pts had INT-risk cytogenetics (AZA n=155 [64%], CCR n=160 [65%]), including 218 who were CN (AZA n=113 [73%], CCR n=105 [66%]), and 170 pts had poor-risk cytogenetics (AZA n=85 [35%], CCR n=85 [34%]). Within each of the 3 cytogenetic risk subgroups, the distribution of pts receiving individual CCR was very consistent: ~18% of each cytogenetic risk subgroup received BSC, ~64% received LDAC, and ~18% received IC. Baseline characteristics were generally balanced among the AZA and CCR Tx arms and the 3 cytogenetic risk groups (Table). At baseline, proportionately more pts with poor-risk cytogenetics in the AZA group were aged ≥75 years (57.6% vs 47.1% with CCR) and more pts in the CCR group had AML with myelodysplastic changes (45.9% vs 37.6% with AZA). Median OS (95%CI) in poor-risk pts was significantly prolonged with AZA vs CCR: 6.4 mos (4.2, 8.1) vs 3.2 mos (2.2, 4.7), respectively; HR=0.68 (0.50, 0.94), p=0.019 (Figure). Median OS in INT-risk pts was 13.0 mos (11.2, 16.3) vs 10.1 mos (7.1, 13.3) with AZA vs CCR; HR=0.90 (0.70, 1.16), p=0.41. Median OS in the CN subgroup was 14.1 mos (12.6, 19.5) vs 10.0 mos (6.4, 13.3); HR=0.81 (0.59, 1.10), p=0.18. Estimated 1-year survival was higher with AZA vs CCR in all cytogenetic risk subgroups. Twice the proportion of AZA-treated pts in the poor-risk subgroup were alive at 1 year vs. CCR pts (30.9% vs 14.0%, respectively), a clinically meaningful difference of 16.9% (95%CI 4.4, 29.5). Similarly, in the CN subgroup, 60.7% vs 44.1% of pts were alive at 1 year in the AZA and CCR groups, a difference of 16.5% (3.2, 29.8). AZA effect on 1-year survival in the INT-risk subgroup was also favorable (55.2% vs 45.5% with CCR) (difference 9.7% [-1.4, 20.8]). Grade 3-4 hematologic adverse event rates with AZA were consistent with previous reports (Santini, Eur J Haematol, 2010), with no meaningful differences among all cytogenetic risk groups. Conclusions: Median OS in older pts with AML and poor-risk cytogenetics was meaningfully improved with AZA compared with the CCR currently used for AML, with those pts receiving AZA twice as likely to be alive at 1 year as those treated with CCR. Figure 1 Figure 1. Figure 2 Figure 2. Disclosures Döhner: Celgene: Consultancy. Off Label Use: Use of azacitidine in AML with blast count >30%. Seymour:Celgene: Consultancy, Honoraria, Speakers Bureau. Wierzbowska:Celgene: Honoraria, Speakers Bureau. Selleslag:Celgene: Consultancy, Research Funding, Speakers Bureau. Cavenagh:Celgene: Honoraria. Kumar:Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees. Schuh:Celgene: Membership on an entity's Board of Directors or advisory committees. Candoni:Celgene: Consultancy, Speakers Bureau. Récher:Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding. Sandhu:Celgene: Honoraria. Bernal del Castillo:Celgene: Consultancy. Al-Ali:Celgene: Honoraria, Research Funding. Martinelli:Novartis: Consultancy, Speakers Bureau; BMS: Consultancy, Speakers Bureau; Pfizer: Consultancy; ARIAD: Consultancy. Falantes:Celgene: Consultancy. Stone:Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees. Minden:Celgene: Honoraria. McIntyre:Celgene: Employment. Songer:Celgene: Employment, Equity Ownership. Lucy:Celgene: Employment, Equity Ownership. Beach:Celgene: Employment, Equity Ownership. Dombret:Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees." @default.
• W1040989942 created "2016-06-24" @default.
• W1040989942 creator A5000436961 @default.
• W1040989942 creator A5002489867 @default.
• W1040989942 creator A5003619706 @default.
• W1040989942 creator A5004816154 @default.
• W1040989942 creator A5010990164 @default.
• W1040989942 creator A5015991333 @default.
• W1040989942 creator A5018366313 @default.
• W1040989942 creator A5019086598 @default.
• W1040989942 creator A5026397928 @default.
• W1040989942 creator A5029383123 @default.
• W1040989942 creator A5034231955 @default.
• W1040989942 creator A5037134717 @default.
• W1040989942 creator A5038048073 @default.
• W1040989942 creator A5038099312 @default.
• W1040989942 creator A5041004365 @default.
• W1040989942 creator A5043785211 @default.
• W1040989942 creator A5047810116 @default.
• W1040989942 creator A5053069175 @default.
• W1040989942 creator A5058372035 @default.
• W1040989942 creator A5071023119 @default.
• W1040989942 creator A5073761054 @default.
• W1040989942 creator A5081326206 @default.
• W1040989942 creator A5089395073 @default.
• W1040989942 date "2014-12-06" @default.
• W1040989942 modified "2023-10-02" @default.
• W1040989942 title "Overall Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with >30% Bone Marrow Blasts Treated with Azacitidine By Cytogenetic Risk Status: Results of the AZA-AML-001 Study" @default.
• W1040989942 doi "https://doi.org/10.1182/blood.v124.21.621.621" @default.
• W1040989942 hasPublicationYear "2014" @default.
• W1040989942 type Work @default.
• W1040989942 sameAs 1040989942 @default.
• W1040989942 citedByCount "7" @default.
• W1040989942 countsByYear W10409899422015 @default.
• W1040989942 countsByYear W10409899422017 @default.
• W1040989942 countsByYear W10409899422018 @default.
• W1040989942 countsByYear W10409899422021 @default.
• W1040989942 crossrefType "journal-article" @default.
• W1040989942 hasAuthorship W1040989942A5000436961 @default.
• W1040989942 hasAuthorship W1040989942A5002489867 @default.
• W1040989942 hasAuthorship W1040989942A5003619706 @default.
• W1040989942 hasAuthorship W1040989942A5004816154 @default.
• W1040989942 hasAuthorship W1040989942A5010990164 @default.
• W1040989942 hasAuthorship W1040989942A5015991333 @default.
• W1040989942 hasAuthorship W1040989942A5018366313 @default.
• W1040989942 hasAuthorship W1040989942A5019086598 @default.
• W1040989942 hasAuthorship W1040989942A5026397928 @default.
• W1040989942 hasAuthorship W1040989942A5029383123 @default.
• W1040989942 hasAuthorship W1040989942A5034231955 @default.
• W1040989942 hasAuthorship W1040989942A5037134717 @default.
• W1040989942 hasAuthorship W1040989942A5038048073 @default.
• W1040989942 hasAuthorship W1040989942A5038099312 @default.
• W1040989942 hasAuthorship W1040989942A5041004365 @default.
• W1040989942 hasAuthorship W1040989942A5043785211 @default.
• W1040989942 hasAuthorship W1040989942A5047810116 @default.
• W1040989942 hasAuthorship W1040989942A5053069175 @default.
• W1040989942 hasAuthorship W1040989942A5058372035 @default.
• W1040989942 hasAuthorship W1040989942A5071023119 @default.
• W1040989942 hasAuthorship W1040989942A5073761054 @default.
• W1040989942 hasAuthorship W1040989942A5081326206 @default.
• W1040989942 hasAuthorship W1040989942A5089395073 @default.
• W1040989942 hasBestOaLocation W10409899421 @default.
• W1040989942 hasConcept C104317684 @default.
• W1040989942 hasConcept C126322002 @default.
• W1040989942 hasConcept C143998085 @default.
• W1040989942 hasConcept C150194340 @default.
• W1040989942 hasConcept C174475383 @default.
• W1040989942 hasConcept C190727270 @default.
• W1040989942 hasConcept C2776239401 @default.
• W1040989942 hasConcept C2778461978 @default.
• W1040989942 hasConcept C2778729363 @default.
• W1040989942 hasConcept C2780007613 @default.
• W1040989942 hasConcept C2780235182 @default.
• W1040989942 hasConcept C30481170 @default.
• W1040989942 hasConcept C55493867 @default.
• W1040989942 hasConcept C71924100 @default.
• W1040989942 hasConcept C86803240 @default.
• W1040989942 hasConceptScore W1040989942C104317684 @default.
• W1040989942 hasConceptScore W1040989942C126322002 @default.
• W1040989942 hasConceptScore W1040989942C143998085 @default.
• W1040989942 hasConceptScore W1040989942C150194340 @default.
• W1040989942 hasConceptScore W1040989942C174475383 @default.
• W1040989942 hasConceptScore W1040989942C190727270 @default.
• W1040989942 hasConceptScore W1040989942C2776239401 @default.
• W1040989942 hasConceptScore W1040989942C2778461978 @default.
• W1040989942 hasConceptScore W1040989942C2778729363 @default.
• W1040989942 hasConceptScore W1040989942C2780007613 @default.
• W1040989942 hasConceptScore W1040989942C2780235182 @default.
• W1040989942 hasConceptScore W1040989942C30481170 @default.
• W1040989942 hasConceptScore W1040989942C55493867 @default.
• W1040989942 hasConceptScore W1040989942C71924100 @default.
• W1040989942 hasConceptScore W1040989942C86803240 @default.
• W1040989942 hasIssue "21" @default.
• W1040989942 hasLocation W10409899421 @default.
• W1040989942 hasOpenAccess W1040989942 @default.
• W1040989942 hasPrimaryLocation W10409899421 @default.
• W1040989942 hasRelatedWork W2007153145 @default.
• W1040989942 hasRelatedWork W2052878752 @default.

• next